BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan.
Stock data | 2024 | Change |
---|---|---|
Price | $1.20 | N/A |
Market Cap | $147.19M | N/A |
Shares Outstanding | 123.08M | N/A |
Employees | 0 | N/A |